Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 144 publications
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
Journal: Science translational medicine
Published: July 29, 2026
Hattrick against Lymphoma with Trispecific CAR T Cells.
Journal: Blood cancer discovery
Published: July 21, 2026
The future of ciltacabtagene autoleucel in multiple myeloma has just begun.
Journal: Nature reviews. Clinical oncology
Published: July 14, 2026
Publisher Correction: Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.
Journal: NPJ digital medicine
Published: June 16, 2026
Low muscle quality, but not muscle mass, in abdominal CT-scans associates with adverse outcomes in AML patients undergoing an allogeneic stem cell transplantation.
Journal: Bone marrow transplantation
Published: April 11, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.
Journal: Journal of hematology & oncology
Published: April 06, 2026
Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients.
Journal: Bone marrow transplantation
Published: March 20, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.
Journal: Bone marrow transplantation
Published: February 19, 2026
Last Updated: 09/26/2026